ProPhase Labs, Inc. Revenues
ProPhase Labs, Inc. (PRPH) reported Revenues of $24.20 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Income Statement › Revenue
us-gaap:Revenues · last filed 2022-11-10
- ProPhase Labs, Inc. revenues for the quarter ending 2022-09-30 was $24.20M, a 154.74% increase year-over-year.
- ProPhase Labs, Inc. revenues for the quarter ending 2022-06-30 was $29.10M, a 219.78% increase year-over-year.
- ProPhase Labs, Inc. revenues for the quarter ending 2022-03-31 was $47.50M, a 210.46% increase year-over-year.
- ProPhase Labs, Inc. revenues for the quarter ending 2021-09-30 was $9.50M.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month |
|---|---|---|---|
| 2022-09-30 | $24.20M 10-Q · filed 2022-11-10 | $53.30M derived: sum of 2 quarters · filed 2022-11-10 | $100.80M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $29.10M 10-Q · filed 2022-08-12 | $76.60M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $47.50M 10-Q · filed 2022-05-13 | ||
| 2021-09-30 | $9.50M 10-Q · filed 2022-11-10 | $18.60M derived: sum of 2 quarters · filed 2022-11-10 | $33.90M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $9.10M 10-Q · filed 2022-08-12 | $24.40M 10-Q · filed 2022-08-12 | |
| 2021-03-31 | $15.30M 10-Q · filed 2022-05-13 | ||
| 2018-03-31 | $3.41M 10-Q/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |